Kaplan-Meier survival analysis showed that the FRscore stratified urologic tumor patients (Imvigor210 cohort) into two subgroups with distinct clinical outcomes, with the high-FRscore subgroup showing a poor response to anti-PD-L1 therapy (Figure 7(d), p = 0.013, log-rank test). Here, CD274 is linked to neoplasm.